Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Sukhmani K. Padda(Stanford University), Sunil Badve(Emory University), Heather A. Wakelee(Palo Alto Institute), James Huang(National University Health System), Yue Shang(Dalian Medical University), Alberto Antonicelli(Yale University), Jonathan W. Riess(University of California Davis Medical Center), Joseph B. Shrager(Stanford Medicine), Robert J. Korst(Bristol-Myers Squibb (Germany)), Xiaopan Yao(Dana-Farber Cancer Institute), Frank Detterbeck(Yale University), Bryan M. Burt(Baylor College of Medicine)
Cited by 97
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
|Journal of Clinical Oncology|2014|1.3k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k